Refine
Has Fulltext
- yes (5)
Is part of the Bibliography
- yes (5)
Document Type
- Journal article (4)
- Doctoral Thesis (1)
Keywords
- ABCG2 (1)
- Aquaporine (1)
- Biomarker (1)
- CML (1)
- GFP (1)
- Genexpression (1)
- Genregulation (1)
- Imatinib (1)
- M1/M2 macrophages (1)
- Pflanzen (1)
Institute
EU-Project number / Contract (GA) number
- 229289 (1)
Analytical ultracentrifugation (AUC) is a first principles based method to determine absolute sedimentation coefficients and buoyant molar masses of macromolecules and their complexes, reporting on their size and shape in free solution. The purpose of this multi-laboratory study was to establish the precision and accuracy of basic data dimensions in AUC and validate previously proposed calibration techniques. Three kits of AUC cell assemblies containing radial and temperature calibration tools and a bovine serum albumin (BSA) reference sample were shared among 67 laboratories, generating 129 comprehensive data sets. These allowed for an assessment of many parameters of instrument performance, including accuracy of the reported scan time after the start of centrifugation, the accuracy of the temperature calibration, and the accuracy of the radial magnification. The range of sedimentation coefficients obtained for BSA monomer in different instruments and using different optical systems was from 3.655 S to 4.949 S, with a mean and standard deviation of (4.304\(\pm\)0.188) S (4.4%). After the combined application of correction factors derived from the external calibration references for elapsed time, scan velocity, temperature, and radial magnification, the range of s-values was reduced 7-fold with a mean of 4.325 S and a 6-fold reduced standard deviation of \(\pm\)0.030 S (0.7%). In addition, the large data set provided an opportunity to determine the instrument-to-instrument variation of the absolute radial positions reported in the scan files, the precision of photometric or refractometric signal magnitudes, and the precision of the calculated apparent molar mass of BSA monomer and the fraction of BSA dimers. These results highlight the necessity and effectiveness of independent calibration of basic AUC data dimensions for reliable quantitative studies.
Within the EURO-SKI trial, 132 chronic phase CML patients discontinued imatinib treatment. RNA was isolated from peripheral blood in order to analyze the expression of MDR1, ABCG2 and OCT1. ABCG2 was predictive for treatment-free remission in Cox regression analysis. High transcript levels of the ABCG2 efflux transporter (>4.5 parts per thousand) were associated with a twofold higher risk of relapse. Introduction: Tyrosine kinase inhibitors (TKIs) can safely be discontinued in chronic myeloid leukemia (CML) patients with sustained deep molecular response. ABCG2 (breast cancer resistance protein), OCT1 (organic cation transporter 1), and ABCB1 (multidrug resistance protein 1) gene products are known to play a crucial role in acquired pharmacogenetic TKI resistance. Their influence on treatment-free remission (TFR) has not yet been investigated. Materials and Methods: RNA was isolated on the last day of TKI intake from peripheral blood leukocytes of 132 chronic phase CML patients who discontinued TKI treatment within the European Stop Tyrosine Kinase Inhibitor Study trial. Plasmid standards were designed including subgenic inserts of OCT1, ABCG2, and ABCB1 together with GUSB as reference gene. For expression analyses, quantitative real-time polymerase chain reaction was used. Multiple Cox regression analysis was performed. In addition, gene expression cutoffs for patient risk stratification were investigated. Results: The TFR rate of 132 patients, 12 months after TKI discontinuation, was 54% (95% confidence interval [CI], 46%-62%). ABCG2 expression (parts per thousand) was retained as the only significant variable (P=.02; hazard ratio, 1.04; 95% CI, 1.01-1.07) in multiple Cox regression analysis. Only for the ABCG2 efflux transporter, a significant cutoff was found (P=.04). Patients with an ABCG2/GUSB transcript level >4.5 parts per thousand (n=93) showed a 12-month TFR rate of 47% (95% CI, 37%-57%), whereas patients with low ABCG2 expression (<= 4.5 parts per thousand; n=39) had a 12-month TFR rate of 72% (95% CI, 55%-82%). Conclusion: In this study, we investigated the effect of pharmacogenetics in the context of a CML treatment discontinuation trial. The transcript levels of the efflux transporter ABCG2 predicted TFR after TKI discontinuation. (C) 2018 The Authors. Published by Elsevier Inc.
Die Methodik und Technik der Gaswechselmessung von Pflanzen wurde für den Modellorganismus Arabidopsis thaliana optimiert und für Untersuchungen zur Beteiligung des Aquaporins PIP1b an Wassertransportvorgängen während der Stomaöffnung verwendet. Die Messungen der Transpirationsraten von PIP1b-Antisense-Pflanzen ergaben keine Hinweise auf Veränderungen des zeitlichen Verlaufs der Stomaöffnung. Die Wasserpermeabilitäten von Schließzell-Plasmamembranen scheinen somit nicht von der Expression des Aquaporins PIP1b beeinflußt zu sein. - Gaswechselmessungen an Nicotiana tabacum NtAQP1-Antisense-Pflanzen zeigten eine Verringerung der Transpirationsraten im Licht und eine geringere Grundtranspiration im Dunkeln. Dies deutet auf eine Beteiligung von NtAQP1 am Wassertransport hin. - Ausgewählte Arabidopsis thaliana-Mutanten wurden hinsichtlich ihrer stomatären Antwort auf Rot- und Rot-/Blaulicht-Bestrahlung analysiert. Hierfür wurde ein Doppelbestrahlungs-Protokoll entwickelt. Vergleiche mit den Wildtypen ergaben signifikante Unterschiede bei der Phytochrom-Mutante phyA-103, der Abscisinsäure-Mutante aba3-2 und der Auxin-resistenten Mutante axr1-3. Ferner zeigte die Mutante npq1-2 nicht die beschriebene Abweichung der stomatären Antwort auf Blaulicht. - Die Expressionsmuster eines PIP1b-GFP-Reportergens in transgenen Arabidopsis thaliana-Pflanzen wurden analysiert. Hohe Promotor-Aktivitäten konnten in meristematischen Bereichen von Wurzel und Sproß, in Elementen der Leitbündel, in jungen Kotyledonen und in Staubblättern beobachtet werden. Es zeigte sich eine enge Korrelation zwischen PIP1b-Promotoraktivität und Streckungswachstum. - Eine Sequenzanalyse des NtAQP1-Promotors ergab Übereinstimmungen mit spezifischen Bindungsmotiven von MYB-ähnlichen Transkriptionsfaktoren. Mit Promotor-Reportergenen konnte die Beteiligung eines dieser Sequenzmotive an der GA- und ABA-induzierten Aktivierung des NtAQP1-Promotors gezeigt werden. Zur Analyse der Phytohormon-Wirkungen auf deletierte Promotorbereiche wurde ein duales Vektorsystem entwickelt und bei der transienten Transformation von BY2-Protoplasten eingesetzt. - Die Expression eines GFP::NtAQP1-Fusionsgens in BY2-Zellen zeigte die subzelluläre Lokalisation des Aquaporins in der Zytoplasmamembran. Ferner wurde Fusionsprotein in Vesikel-ähnlichen Strukturen beobachtet.
Stimulating the immune system to attack cancer is a promising approach, even for the control of advanced cancers. Several cytokines that promote interferon-γ-dominated immune responses show antitumor activity, with interleukin 12 (IL-12) being of major importance. Here, we used an antibody-IL-12 fusion protein (NHS-IL12) that binds histones of necrotic cells to treat human sarcoma in humanized mice. Following sarcoma engraftment, NHS-IL12 therapy was combined with either engineered IL-7 (FcIL-7) or IL-2 (IL-2MAB602) for continuous cytokine bioavailability. NHS-IL12 strongly induced innate and adaptive antitumor immunity when combined with IL-7 or IL-2. NHS-IL12 therapy significantly improved survival of sarcoma-bearing mice and caused long-term remissions when combined with IL-2. NHS-IL12 induced pronounced cancer cell senescence, as documented by strong expression of senescence-associated p16\(^{INK4a}\) and nuclear translocation of p-HP1γ, and permanent arrest of cancer cell proliferation. In addition, this cancer immunotherapy initiated the induction of myogenic differentiation, further promoting the hypothesis that efficient antitumor immunity includes mechanisms different from cytotoxicity for efficient cancer control in vivo.
Background: Data from clinical studies and results from animal models suggest an involvement of the neurotrophin system in the pathology of depression and antidepressant treatment response. Genetic variations within the genes coding for the brain-derived neurotrophic factor (BDNF) and its key receptor Trkb (NTRK2) may therefore influence the response to antidepressant treatment.
Methods: We performed a single and multi-marker association study with antidepressant treatment outcome in 398 depressed Caucasian inpatients participating in the Munich Antidepressant Response Signature (MARS) project. Two Caucasian replication samples (N = 249 and N = 247) were investigated, resulting in a total number of 894 patients. 18 tagging SNPs in the BDNF gene region and 64 tagging SNPs in the NTRK2 gene region were genotyped in the discovery sample; 16 nominally associated SNPs were tested in two replication samples.
Results: In the discovery analysis, 7 BDNF SNPs and 9 NTRK2 SNPs were nominally associated with treatment response. Three NTRK2 SNPs (rs10868223, rs1659412 and rs11140778) also showed associations in at least one replication sample and in the combined sample with the same direction of effects (\(P_{corr}\) = .018, \(P_{corr}\) = .015 and \(P_{corr}\) = .004, respectively). We observed an across-gene BDNF-NTRK2 SNP interaction for rs4923468 and rs1387926. No robust interaction of associated SNPs was found in an analysis of BDNF serum protein levels as a predictor for treatment outcome in a subset of 93 patients.
Conclusions/Limitations: Although not all associations in the discovery analysis could be unambiguously replicated, the findings of the present study identified single nucleotide variations in the BDNF and NTRK2 genes that might be involved in antidepressant treatment outcome and that have not been previously reported in this context. These new variants need further validation in future association studies.